| Page 1735 | Kisaco Research
 
Senior Living Transformation Technology Leaders Summit
22-31 Mar 2021
Virtual Summit
In the past many senior care and housing providers have not had the risk appetite to drive digital transformation and adopt new technologies within their business. The pandemic has forced the hand of many risk adverse boards and executives to see the business-critical role technology, and the data it generates can play in facing this monumental disruption to normal operating models.Now is the time for senior care executives to take a step back, assess what technology is right for their current and future business needs and build a strategic roadmap for how to get there.The Senior Living Transformation:Technology Leaders virtual series will provide you with  practical workshops, interactive roundtables and executive panels. Each individual session has been designed in response to feedback from the leaders in the senior care industry.This March we will be tackling how to:Determine the right connectivity and infrastructure required to adapt to the ‘new normal’Implement and maximize resident experience technologyLeverage sales and marketing technology & lead digital transformationBuild and execute an IT roadmap and strategyPilot and implement a successful innovation and technology pilot program  This series is perfect for executives ready to build and execute a strategic IT roadmap at their organization and who are determining the priority areas for their budget.
Visit Site
 

Sadia L'Bouch

Senior Director, Manufacturing and Supply
Sangamo Therapeutics

Sadia L'Bouch

Senior Director, Manufacturing and Supply
Sangamo Therapeutics

Sadia L'Bouch

Senior Director, Manufacturing and Supply
Sangamo Therapeutics
 

Pierre Heimendinger

VP Process Development
Sangamo Therapeutics

Pierre Heimendinger

VP Process Development
Sangamo Therapeutics

Pierre Heimendinger

VP Process Development
Sangamo Therapeutics
 

Markwin Velders

MD & VP Operations
Kite Pharma

Markwin Velders

MD & VP Operations
Kite Pharma

Markwin Velders

MD & VP Operations
Kite Pharma
 

Jean-Pierre Latere Dwan’Isa

COO
Celyad

Jean-Pierre Latere Dwan’Isa

COO
Celyad

Jean-Pierre Latere Dwan’Isa

COO
Celyad
 

Jasmin Kee

VP Manufacturing Operations
Cell Medica

Jasmin Kee

VP Manufacturing Operations
Cell Medica

Jasmin Kee

VP Manufacturing Operations
Cell Medica
 

Dr. Machteld Tiemessen

Team Leader, Immunology
Danone Nutricia Research

In July 2018, Dr. Machteld Tiemessen joined Danone Nutricia Research as Team Leader Immunology in the Global Center of Excellence Immunology. Since obtaining her PhD in Immunology in 2004, which was focused on the induction of oral tolerance in food allergy, she has held many different positions, both at academia and in industry. The main topic at the start of her career was the investigation of the role and mechanisms of regulatory T cells in normal immune responses and during diseases, such as allergy and cutaneous T cell lymphoma.

Read full bio

Dr. Machteld Tiemessen

Team Leader, Immunology
Danone Nutricia Research

Dr. Machteld Tiemessen

Team Leader, Immunology
Danone Nutricia Research

In July 2018, Dr. Machteld Tiemessen joined Danone Nutricia Research as Team Leader Immunology in the Global Center of Excellence Immunology. Since obtaining her PhD in Immunology in 2004, which was focused on the induction of oral tolerance in food allergy, she has held many different positions, both at academia and in industry. The main topic at the start of her career was the investigation of the role and mechanisms of regulatory T cells in normal immune responses and during diseases, such as allergy and cutaneous T cell lymphoma. In 2010, she received a Veni-grant to further elucidate the role of Wnt-signaling in peripheral T cell function (not restricted to regulatory T cells). After 14 years of research at several universities in The Netherlands and King’s College in London, the United Kingdom, she started in 2013 at Johnson & Johnson to apply her immunological knowledge in the field of viral vaccines. At J&J, she led various discovery projects, with a focus on early discovery projects in the field of oncology vaccines and in the field of polio vaccines.

MINTEL REPORT: Why Personalisation is the Future of Beauty
 

Richard Russell

Group Commercial Director
RES Group

With over 10 years of experience in the renewable energy sector in various group finance, operational finance and latterly commercial roles.

RES Group is an independent developer, constructor and asset manager of grid connected renewable energy infrastructure. RES Group has delivered over 16 GW of new renewable energy projects to date, including the construction of almost 10% of the wind energy capacity in the USA, and is active in a range of energy technologies including onshore and offshore wind, solar, energy storage and transmission and distribution.

Read full bio

Richard Russell

Group Commercial Director
RES Group

Richard Russell

Group Commercial Director
RES Group

With over 10 years of experience in the renewable energy sector in various group finance, operational finance and latterly commercial roles.

RES Group is an independent developer, constructor and asset manager of grid connected renewable energy infrastructure. RES Group has delivered over 16 GW of new renewable energy projects to date, including the construction of almost 10% of the wind energy capacity in the USA, and is active in a range of energy technologies including onshore and offshore wind, solar, energy storage and transmission and distribution.

Prior to RES, Richard worked within PwC’s assurance and audit practice. Richard is a Chartered Accountant and holds an honours degree in Economics from Durham University

 
Microbiome Connect - Skin - USA 2020
3-5 Jun 2020
VIRTUAL SUMMIT | EDT Timezone
2019 was a pivotal year for the skin microbiome, with multinational conglomerates moving into the space, recognizing the commercial value of skin microbiome-based products as the next step in a consumer’s skincare regime but the innovation doesn’t end there…This year is all about the major advancements of sequencing and analysis in this space, and how we can use data to inform product development. 2020 is all about the relationship between skin microbiome based-products, skin conditions, personalization, skin-gut supplements, and anti-aging. Building on the hugely successful global Skin Microbiome series which brought together over 600 industry leaders from Pharmaceutical, Beauty and Personal Care, Independent Skincare Brands, Bio-techs, Researchers and Academics, Kisaco Research presents Microbiome Connect: Skin USA, an all-encompassing event, which runs alongside Microbiome Connect: Human USA as a virtual event, June 3 - 5.What’s different?This year, you can expect 5 unique topics, more attendees and more networking opportunities to explore:Ground-breaking research into how best treat these skin diseases and develop treatments targeting acne vulgaris, atopic dermatitis, psoriasis Vulgaris and rosacea.The translation and commercialization of product claims, the latest trends and protecting your intellectual property.The convergence between the skin-gut axis and the supplement market.Personalized formulation and product developmentTools to increase product claims using sequencing and bioinformatics.Join key opinion leaders and expert speakers across three days to translate the latest skin microbiome data and market analysis into truly commercial and competitive beauty and personal care products.Skin microbiome based-products have been disrupting the beauty industry for the past two years, the question is, how can you differentiate your products?
Visit Site